TY - JOUR
T1 - Cachexia
T2 - A new definition
AU - Evans, William J.
AU - Morley, John E.
AU - Argilés, Josep
AU - Bales, Connie
AU - Baracos, Vickie
AU - Guttridge, Denis
AU - Jatoi, Aminah
AU - Kalantar-Zadeh, Kamyar
AU - Lochs, Herbert
AU - Mantovani, Giovanni
AU - Marks, Daniel
AU - Mitch, William E.
AU - Muscaritoli, Maurizio
AU - Najand, Armine
AU - Ponikowski, Piotr
AU - Rossi Fanelli, Filippo
AU - Schambelan, Morrie
AU - Schols, Annemie
AU - Schuster, Michael
AU - Thomas, David
AU - Wolfe, Robert
AU - Anker, Stefan D.
PY - 2008/12
Y1 - 2008/12
N2 - On December 13th and 14th a group of scientists and clinicians met in Washington, DC, for the cachexia consensus conference. At the present time, there is no widely agreed upon operational definition of cachexia. The lack of a definition accepted by clinician and researchers has limited identification and treatment of cachectic patient as well as the development and approval of potential therapeutic agents. The definition that emerged is: "cachexia, is a complex metabolic syndrome associated with underlying illness and characterized by loss of muscle with or without loss of fat mass. The prominent clinical feature of cachexia is weight loss in adults (corrected for fluid retention) or growth failure in children (excluding endocrine disorders). Anorexia, inflammation, insulin resistance and increased muscle protein breakdown are frequently associated with cachexia. Cachexia is distinct from starvation, age-related loss of muscle mass, primary depression, malabsorption and hyperthyroidism and is associated with increased morbidity. While this definition has not been tested in epidemiological or intervention studies, a consensus operational definition provides an opportunity for increased research.
AB - On December 13th and 14th a group of scientists and clinicians met in Washington, DC, for the cachexia consensus conference. At the present time, there is no widely agreed upon operational definition of cachexia. The lack of a definition accepted by clinician and researchers has limited identification and treatment of cachectic patient as well as the development and approval of potential therapeutic agents. The definition that emerged is: "cachexia, is a complex metabolic syndrome associated with underlying illness and characterized by loss of muscle with or without loss of fat mass. The prominent clinical feature of cachexia is weight loss in adults (corrected for fluid retention) or growth failure in children (excluding endocrine disorders). Anorexia, inflammation, insulin resistance and increased muscle protein breakdown are frequently associated with cachexia. Cachexia is distinct from starvation, age-related loss of muscle mass, primary depression, malabsorption and hyperthyroidism and is associated with increased morbidity. While this definition has not been tested in epidemiological or intervention studies, a consensus operational definition provides an opportunity for increased research.
KW - Anorexia
KW - Inflammation
KW - Involuntary weight loss
KW - Muscle wasting
KW - Wasting disease
UR - https://www.scopus.com/pages/publications/55749085001
U2 - 10.1016/j.clnu.2008.06.013
DO - 10.1016/j.clnu.2008.06.013
M3 - Article
C2 - 18718696
AN - SCOPUS:55749085001
SN - 0261-5614
VL - 27
SP - 793
EP - 799
JO - Clinical Nutrition
JF - Clinical Nutrition
IS - 6
ER -